What Hamari Chemicals does

Hamari Chemicals (浜理薬品工業株式会社) is a privately held Japanese pharmaceutical contract development and manufacturing organization (CDMO) founded in 1947 and headquartered in Osaka. The company manufactures active pharmaceutical ingredients (APIs) and intermediates across the full drug lifecycle — from drug discovery support and preclinical work through clinical trial supply to commercial production — for Japanese branded and generic pharmaceutical companies, international pharma firms, and peptide drug developers. Approximately 90% of revenue is generated domestically in Japan, with the balance from export sales.

Its core technology platform rests on proprietary chiral chemistry capabilities: the in-house HAMOC ruthenium-based asymmetric hydrogenation catalyst, the co-developed Soloshonok-Hamari chiral ligand for non-natural amino acid synthesis, and a patented humidification drying method that reduces residual solvent levels from over 3,000 ppm to below 200 ppm at up to 20 kg scale. The company also operates solid-phase and liquid-phase peptide synthesis (including high-potency peptide APIs at Category 4 containment), continuous flow chemistry developed since 2016, and supports high-potency API (HPAPI) manufacturing. Manufacturing is distributed across three Japanese sites — Osaka (HQ and research), Yonezawa (100t-scale GMP API production, FDA-inspected since 2006, fully renewable hydroelectric power since August 2025), and Chitose (GMP peptide and intermediate production, plus food extract processing).

Hamari operates a project-fee and contract-manufacturing revenue model, selling directly to enterprise pharmaceutical customers through dedicated sales departments (営業第一課, 営業第二課) and an international department, with a wholly-owned trading subsidiary in Shanghai and a US sales entity. The portfolio also extends to commercial generic APIs (Polaprezinc, Tamsulosin HCl, Edaravone, Ibuprofen), tailor-made non-natural amino acids sold as catalog products, and consumer health supplements (L-Carnosine, imidazole peptides) via subsidiary Hamari Pharmaceutical Nutritional Science. A holding company, HAMARI holdings, was established in October 2023 over the operating group.

Name

Hamari Chemicals

Legal name

浜理薬品工業株式会社

Website

https://hamarichemicals.com

Company type

Private

Founded year

1947

Operating status

Operating

Short description

Hamari Chemicals is a Japanese pharmaceutical CDMO (founded 1947, Osaka) that manufactures chiral APIs, intermediates, peptide APIs, and non-natural amino acids for branded, generic, and international pharma customers across three domestic GMP sites.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical API manufacturing
• Contract development manufacturing
• Peptide synthesis services
• Asymmetric synthesis catalysts
• Custom amino acid synthesis

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations

Revenue model

1. Pharmaceutical API / Intermediate CDMO Manufacturing: Contract development and manufacturing services for pharmaceutical active pharmaceutical ingredients and intermediates. Covers the full drug development lifecycle from drug discovery support through preclinical, clinical trial, manufacturing application, and commercial production. Revenue generated through project fees, manufacturing fees, and product supply contracts with pharmaceutical companies.
2. Commercial API and Intermediate Product Sales: Sale of manufactured pharmaceutical APIs and intermediates, including branded generic products such as Polaprezinc (ポラプレジンク), Tamsulosin HCl, Edaravone, Ibuprofen, Ketoprofen, Levocarnitine, and others. Also includes non-natural amino acids (tailor-made amino acids) sold as catalog products.
3. Health Supplement and Food Ingredient Sales: Sale of health supplement products (L-Carnosine, Imidazole peptides, α-Lipoic acid, Acetylglucosamine) through subsidiary Hamari Pharmaceutical Nutritional Science and Hamari产业. Also includes food extract and powder processing services from Chitose factory.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Hamari Chemicals is a pharmaceutical contract development and manufacturing organization (CDMO) that develops, synthesizes, and manufactures active pharmaceutical ingredients (APIs) and intermediates for branded and generic drug makers across small-molecule and peptide therapeutics. Core offerings include API process development and GMP manufacturing, asymmetric synthesis using the proprietary HAMOC catalyst, tailor-made (non-natural) amino acid synthesis via the Soloshonok-Hamari Ligand, peptide API manufacturing using both solid-phase and liquid-phase methods, and continuous flow chemistry production, all delivered from three GMP-compliant facilities in Japan (Osaka, Yonezawa, Chitose) with FDA-inspected capability.

Product overview

Hamari Chemicals is a pharmaceutical contract development and manufacturing organization (CDMO) offering integrated services from drug discovery to commercial production. The core offerings include API manufacturing (low-molecule and peptide APIs), tailor-made amino acid synthesis, asymmetric synthesis using proprietary HAMOC® catalyst technology, and continuous flow synthesis. Manufacturing is conducted across three facilities in Japan (Osaka, Yonezawa, Chitose) with GMP compliance and FDA inspection approval. The company also provides food extract processing services and health ingredient products including pure carnosine.

Differentiator

Problem solved

Functional benefit

Brands

• HAMOC: Proprietary asymmetric hydrogenation catalyst technology for chiral synthesis
• Polaprezinc HAMARI Y
• Tamsulosin HCl HAMARI
• Pure Carnosine
• Carnopower ENERGY

Products and services

• Active Pharmaceutical Ingredient (API) Manufacturing Service (原薬製造サービス) Comprehensive pharmaceutical API manufacturing services from drug discovery through commercial production, including process development, scale-up, GMP manufacturing, and process validation for small-molecule APIs. Targeted at domestic and international branded and generic pharmaceutical companies.
• Peptide API Manufacturing (ペプチド原薬) Peptide pharmaceutical ingredient manufacturing using both solid-phase and liquid-phase synthesis methods, supporting short- to medium-chain peptides from gram to kilogram scale including high-potency peptide API manufacturing under cGMP.
• Tailor-made Amino Acids (テーラーメイドアミノ酸) Custom non-natural amino acid synthesis service using proprietary chiral Ni(II)-complex technology, available as free bodies, Fmoc-forms, and Boc-forms for pharmaceutical and peptide applications.
• HAMOC Asymmetric Hydrogenation Catalyst (不斉合成 HAMOC®) Proprietary asymmetric hydrogenation catalyst technology for synthesizing optical active pharmaceutical intermediates with high stereoselectivity, available as an enabling capability within Hamari's CDMO services and as branded technology.
• Flow Synthesis / Continuous Production (フロー合成・連続生産) Continuous flow synthesis service for API manufacturing, improving production efficiency, safety, and environmental footprint versus traditional batch methods under GMP.
• Humidification Drying / Solvent Removal by Humidification (調湿乾燥・加湿脱溶媒) Proprietary humidity-controlled drying technology for residual solvent reduction in pharmaceutical manufacturing, replacing solvent molecules with water molecules using filtered drying equipment combined with humidity conditioning.
• Soloshonok-Hamari Ligand Proprietary chiral ligand enabling highly stereoselective synthesis of non-natural amino acids, recyclable for cost-effective large-scale synthesis, offered as part of Hamari's custom synthesis services.
• High Potency Active Pharmaceutical Ingredient (HPAPI) Manufacturing (高薬理活性原薬製造) High-potency API manufacturing with Category 4 hazard containment, including reactors, centrifugal separators, filter dryers, pin mill for milling, and injectable API manufacturing capabilities.
• Food Extract / OEM Processing (食品コラーゲン・抽出OEM) Food extract and powder processing services utilizing facilities at Chitose Factory, supporting product development and contract manufacturing for food ingredients using Hokkaido-sourced raw materials.
• Pure Carnosine (ピュアカルノシン) Anti-fatigue imidazole dipeptide ingredient with odorless, tasteless profile and 99%+ purity content, used in supplements and also supplied via patented L-2-oxocarnosine manufacturing (WO2026/075272).
• Polaprezinc "Hamari Y" (ポラプレジンク "ハマリY") Hamari's proprietary anti-gastric ulcer API (zinc L-carnosine complex) sold as a branded pharmaceutical ingredient to generic drug manufacturers.
• Tamsulosin Hydrochloride "Hamari" (タムスロシン塩酸塩 "ハマリ") Hamari-branded Tamsulosin HCl API sold for the treatment of urinary disturbance associated with benign prostatic hyperplasia.

Quantifiable outcome

• Residual solvent reduction from ≥3000ppm to <200ppm using humidification drying technology
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PeptideStar Co., Ltd. (ペプチスター株式会社)coreStrategic or Co-development Partner · 20 April 2018Investment and strategic partnership in PeptideStar, a Japanese peptide CDMO company established by PeptideDream, Shionogi, and Sekisui Chemical. Hamari contributes its proprietary non-natural amino acid synthesis technology and quality assurance systems to support special peptide drug development and manufacturing.
• Nakarai Tesque Co., Ltd. (ナカライテスク株式会社)minorChannel Partner/ Reseller/ DistributorNakarai Tesque serves as a distributor for L-2-oxocarnosine (L-2-oxoimidazole dipeptide) samples under Hamari's patent license. Samples are available for purchase through Nakarai's commercial catalog.
• Oji Holdings Corporation (王子ホールディングス株式会社)minorStrategic or Co-development PartnerJoint development partnership with Oji Holdings for practical application of polysulfated pentosan sodium (PPS) as a pharmaceutical API. Both human and veterinary pharmaceutical applications are being developed jointly.
• Maruishi Pharmaceutical Co., Ltd. (丸石製薬株式会社)coreStrategic or Co-development PartnerJoint development of novel broad-spectrum disinfectant compounds effective against MRSA and gram-negative bacteria. Hamari supplies the active pharmaceutical compounds while Maruishi handles formulation, product development, and global sales. Exclusive worldwide development and marketing rights granted to Maruishi.
• Maruten Pharmaceutical Co., Ltd. (丸仁製薬社, Korea)minorChannel Partner/ Reseller/ DistributorExclusive sales rights for Korean-manufactured pharmaceutical-grade Mesima mushroom (Phellinus linteus) products in Japan. Hamari holds exclusive Japanese sales rights for products manufactured using Maruten's patented submerged culture technology.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global CDMO leader across small molecules, biologics, and peptides. Comparable in API CDMO services and serves many of the same large pharmaceutical customers Hamari targets, though at materially larger scale and broader scope.
• WuXi STA (WuXi AppTec): China-based large API CDMO with end-to-end capabilities from preclinical through commercial manufacturing. Competes with Hamari in small-molecule API CDMO globally; a much larger, publicly listed player but with comparable commercial API/intermediate offerings.
• CordenPharma: European-based CDMO offering APIs, drug products, and peptides. Comparable across Hamari's small-molecule and peptide API CDMO offerings, with broader service scope and larger scale.
• Asymchem Laboratories: China-based large-scale CDMO with strong capabilities in chiral and asymmetric synthesis, flow chemistry, and small-molecule API manufacturing. Comparable on chiral chemistry technology stack and serves overlapping pharmaceutical API customers, though at significantly larger scale.

Direct peers

• Jitsubo Co., Ltd. Japanese specialty peptide CDMO focused on non-standard amino acid and peptide synthesis. Comparable to Hamari's tailor-made amino acid and peptide API business in both technology (chiral/non-natural amino acid synthesis) and customer base (Japanese pharma).
• Bachem: Swiss-headquartered global leader in peptide API CDMO. Comparable in peptide manufacturing capabilities (SPPS, liquid-phase, HPAPI) and serves similar pharmaceutical customers with GMP-compliant peptide APIs at scale.
• PolyPeptide Group: Global peptide CDMO specializing in GMP peptide API manufacturing for pharma and biotech. Direct peer in peptide CDMO services, with overlapping capabilities in SPPS/liquid-phase synthesis and high-potency peptide manufacturing.
• PeptideStar Co., Ltd. Japanese peptide CDMO established by PeptideDream, Shionogi, and Sekisui Chemical; Hamari is both a strategic investor and upstream supplier of non-natural amino acids. Directly comparable as a Japan-based peptide API manufacturer serving pharmaceutical customers.

Emerging players

• Sekisui Chemical Co., Ltd. Japanese conglomerate and co-founder of PeptideStar, with growing pharmaceutical CDMO interests. Comparable as a Japanese pharmaceutical/chemical participant adjacent to Hamari's peptide ecosystem through the PeptideStar partnership.

Regional players

• SNBL Group (Shin Nippon Biomedical Laboratories): Japanese-headquartered CRO/CDMO offering preclinical and clinical drug development services. Comparable as a Japan-based pharmaceutical services peer, with overlapping customer base of Japanese and international pharma, though focused earlier in the development lifecycle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@user-vn2wq8ko5y
• Facebookfacebook.com/hamarikenko

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hamari Chemicals